Zhonghua Nei Ke Za Zhi. 2024 Dec 1;63(12):1186-1195. doi: 10.3760/cma.j.cn112138-20240928-00616.
Multiple myeloma (MM), an incurable clonal plasma cell dysplasia, is the second most common hematological malignancy in many countries, mainly developing in the elderly population. With the emergence of novel agents and laboratory methods, the diagnosis and treatment of MM have been significantly improved. In this version of the "Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)", several examination items have been updated in the diagnostic section; the definition of ultra high-risk MM has been proposed in the risk stratification section; for patients with equal or more than second-line relapse, chimeric antigen receptor T cell therapy and a bispecific T-cell engager have been added; and the treatment recommendations have been listed at different levels based on the best available evidence.
多发性骨髓瘤（MM）是一种无法治愈的克隆性浆细胞发育异常疾病，在许多国家是第二常见的血液系统恶性肿瘤，主要发生于老年人群。随着新型药物和实验室方法的出现，MM的诊断和治疗有了显著改善。在本次《中国多发性骨髓瘤诊断与治疗指南（2024年修订版）》中，诊断部分更新了多项检查项目；风险分层部分提出了超高危MM的定义；对于二线及以上复发的患者，增加了嵌合抗原受体T细胞疗法和双特异性T细胞衔接器；并根据现有最佳证据列出了不同级别的治疗建议。
